Una puesta al día en profundidad | 16 MAR 15

¿Qué son las α-talasemias?

Resumen actualizado de los aspectos epidemiológicos de las α-talasemias.
INDICE:  1. Desarrollo | 2. Referencias

1. Weatherall DJ, Clegg JB. Thalassemia - a global public health problem. Nat Med 1996; 2: 847-9.
2. Weatherall DJ. The thalassaemias. BMJ1997; 314:1675-8.
3. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99-109. [Erratum, N Engl J Med 1999; 341:1407.]
4. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86:480-7.
5. Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744-50.
6. Chui DH. Alpha-thalassaemia and population health in Southeast Asia. Ann Hum Biol 2005; 32:123-30.
7. Modiano G, Morpurgo G, Terrenato L, et al. Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population. Am J Hum Genet 1991; 48:390-7.
8. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Mem Fund Q 1971; 49:509-38.
9. Chui DHK, Waye JS. Hydrops fetalis caused by α-thalassemia: an emerging health care problem. Blood 1998; 91:2213-22.
10. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005; 1054:18-24.
11. Weatherall D. The inherited disorders of haemoglobin: an increasingly neglected global health burden. Indian J Med Res 2011; 134:493-7.
12. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115:4331-6.
13. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis 2010; 5:13.
14. Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci 2009; 66: 1154-62.
15. Vichinsky EP. Clinical manifestations of α-thalassemia. Cold Spring Harb Perspect Med 2013; 3:a011742.
16. Galanello R, Cao A. Gene test review: alpha-thalassemia. Genet Med 2011; 13: 83-8.
17. Giardine B, Borg J, Viennas E, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 2014; 42: D1063-D1069.
18. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford, England: Blackwell Science, 2001.
19. Higgs DR. Alpha-thalassaemia. Baillieres Clin Haematol 1993; 6:117-50.
20. Chui DHK, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101:791-800.
21. Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology Am Soc Hematol Educ Program 2009:26-34.
22. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364:710-8.
23. Thein SL. Genetic modifiers of betathalassemia. Haematologica 2005; 90:649-60.
24. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253-7.
25. Ma SK, Au WY, Chan AY, Chan LC. Clinical phenotype of triplicated alphaglobin genes and heterozygosity for beta0- thalassemia in Chinese subjects. Int J Mol Med 2001; 8:171-5.
26. Giordano PC, Bakker-Verwij M, Harteveld CL. Frequency of alpha-globin gene triplications and their interaction with beta-thalassemia mutations. Hemoglobin 2009; 33:124-31.
27. Weatherall DJ, Higgs DR, Bunch C, et al. Hemoglobin H disease and mental retardation: a new syndrome or a remarkable coincidence? N Engl J Med 1981; 305: 607-12.
28. Leung KY, Lee CP, Tang MH, et al. Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn 2004; 24:899-907.
29. Vichinsky EP. Alpha thalassemia major — new mutations, intrauterine management, and outcomes. Hematology Am Soc Hematol Educ Program 2009; 35-41.
30. Wonke B, Modell M, Marlow T, Khan M, Modell B. Microcytosis, iron deficiency and thalassaemia in a multi-ethnic community: a pilot study. Scand J Clin Lab Invest 2007; 67:87-95.
31. Pasvol G. Does alpha+-thalassaemia protect against malaria? PLoS Med 2006; 3(5):e235.
32. Hedrick PW. Population genetics of malaria resistance in humans. Heredity (Edinb) 2011; 107:283-304. [Erratum, Heredity (Edinb) 2011; 107:602.]
33. Penman BS, Habib S, Kanchan K, Gupta S. Negative epistasis between α+ thalassaemia and sickle cell trait can ex- plain interpopulation variation in South Asia. Evolution 2011; 65:3625-32.
34. Penman BS, Pybus OG, Weatherall DJ, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci USA 2009; 106:21242-6.
35. Weatherall DJ. The importance of micromapping the gene frequencies for the common inherited disorders of haemoglobin. Br J Haematol 2010; 149:635-7.
36. Ganczakowski M, Bowden DK, Maitland K, et al. Thalassaemia in Vanuatu, south-west Pacific: frequency and haematological phenotypes of young children. Br J Haematol 1995; 89:485-95.
37. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of hemoglobin. In: Jamison DT, Breman JG, Measham AR, et al., eds. Disease control priorities in developing countries.2nd ed. Washington, DC: World Bank, 2006:663-80.
38. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-223.
39. Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369:448-57.
40. Modell B, Kuliev AM. A scientific basis for cost-benefit analysis of genetics services. Trends Genet 1993; 9:46-52.
41. Ostrowsky JT, Lippman A, Scriver CR. Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health 1985; 75:732-6.
42. Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysisnof national health policy of thalassaemia screening in West-Azerbaijan province of Iran. Int J Prev Med 2012; 3:687-92.
43. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen 1998; 5:120-6.
44. Koren A, Profeta L, Zalman L, et al. Prevention of β thalassemia in northern Israel — a cost-benefit analysis. Mediterr J Hematol Infect Dis 2014; 6:e2014012.
45. Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess 1999; 3:1-186.
46. Padilla CD, Dans LF, Estrada SC, Tamondong MR Jr, Laceste JJ, Bernal RM. Cost-benefit analysis of newborn screening for galactosemia in the Philippines. Southeast Asian J Trop Med Public Health 2003; 34: Suppl 3:215-20.
47. Petrou M, Brugiatelli M, Old J, et al. Alpha thalassaemia hydrops fetalis in the UK: the importance of screening pregnant women of Chinese, other South East Asian and Mediterranean extraction for alpha thalassaemia trait. Br J Obstet Gynaecol 1992; 99:985-9.
48. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood 2000; 95:360-2.
49. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010; 1202:17-23.
50. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007; 30:490-506.
51. de Silva S, Fisher CA, Premawardhena A, et al. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Lancet 2000; 355:786-91.
52. Mills A. Health care systems in lowand middle-income countries. N Engl JMed 2014; 370:552-7.
53. Weatherall D. 2003 William Allan Award address: the thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet 2004; 74:385-92.
54. Higgs DR. The molecular basis of α-thalassemia. Cold Spring Harb Perspect Med 2013; 3:a011718.
55. Benz EJ Jr. Newborn screening for α-thalassemia — keeping up with globalization. N Engl J Med 2011; 364:770-1.
56. Kassebaum NJ, Weatherall D, Naghavi M, Murray CJL. A systematic global analysis of death and disability due to haemoglobinopathies and haemolytic anaemias between 1990 and 2010. Lancet 2013; 381 (Special issue):S73.




Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021